Abstract 18663: Comparative Effectiveness and Safety of Myval versus Contemporary Transcatheter Aortic Valves: A Systematic Review and Network Meta-Analysis
Abstract
Background: Transcatheter aortic valve implantation (TAVI) has become an established alternative to surgical aortic valve replacement for patients with symptomatic severe aortic stenosis. Myval has shown favourable outcomes; however, comparative evidence against established THVs remains limited. Hypothesis: We evaluated the comparative effectiveness and safety of Myval versus contemporary THVs in severe aortic stenosis. Methods: PubMed, Embase, Scopus, Cochrane, and ClinicalTrials.gov were searched through March 2026 for studies comparing Myval with contemporary THVs. Random-effects network meta-analysis was performed. Primary outcomes included PPI, 30-day mortality, stroke, major bleeding, and major vascular complications. Secondary outcomes included technical success, transvalvular aortic regurgitation, mean aortic valve gradient, and 1-year mortality. Risk of bias was assessed using RoB 2 and NOS, and certainty of evidence using CINeMA. Pooled RRs or MDs with 95% CIs were calculated. Results: Twelve studies (2 RCTs and 10 observational studies) comprising 5,444 patients across six THV platforms were included. Compared with Myval, Portico (RR 2.59, 95% CI 1.52-4.42, P-score =0.05) and Allegra (RR 1.99, 95% CI 1.08-3.69, P-score=0.22) were associated with significantly higher PPI rates, while Evolut showed a borderline increase (RR 1.62, 95% CI 0.99-2.66, P-score=0.36). No significant differences were observed between Myval and Sapien or Acurate valves for PPI. 30-day mortality, stroke, major bleeding, and major vascular complications were largely comparable across valves. Evolut showed higher transvalvular aortic regurgitation compared with Myval (RR 2.52, 95% CI 1.35-4.71, P-score=0.01). Technical success was lower with Evolut compared to Myval, whereas Sapien exhibited comparable technical success. For haemodynamics, Allegra (MD –2.26 mmHg, 95% CI –3.10 to –1.42, P-score=1.00) and Evolut (MD –1.37 mmHg, 95% CI –1.99 to –0.75, P-score=0.79) showed significantly lower mean aortic valve gradients than Myval, whereas Sapien had higher gradients (MD +2.70 mmHg, 95% CI +1.90 to +3.50, P-score=0.00). Mortality at 1-year did not differ significantly among valves. No significant publication bias or network inconsistency was detected; overall confidence was low by CINeMA. Conclusion(s): Myval showed a favourable safety and procedural profile compared with contemporary THVs. It had lower permanent pacemaker implantation rates than Portico and Allegra, while maintaining comparable short- and intermediate-term clinical outcomes. Although some supra-annular valves showed lower mean aortic valve gradients, Myval was associated with favorable conduction outcomes while maintaining acceptable haemodynamic performance. Further adequately powered head-to-head randomized controlled trials are needed to confirm these findings.